Literature DB >> 15775993

Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma.

C M Hawrylowicz1, A O'Garra.   

Abstract

Allergic diseases are caused by aberrant T-helper-2 immune responses in susceptible individuals. Both naturally occurring CD4(+)CD25(+) regulatory T cells and inducible populations of antigen-specific interleukin-10-secreting regulatory T cells inhibit these inappropriate immune responses in experimental models. This article discusses the evidence that regulatory T-cell function might be impaired in allergic and asthmatic disease and that certain therapeutic regimens might function, at least in part, to promote regulatory T-cell generation. Current research strategies seek to exploit these observations to improve the generation of allergen-specific regulatory T-cell populations with the potential to provide the safe and long-term alleviation of disease symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775993     DOI: 10.1038/nri1589

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  193 in total

1.  Inducible CD4+LAP+Foxp3- regulatory T cells suppress allergic inflammation.

Authors:  Wei Duan; Takanori So; Amit K Mehta; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.

Authors:  Paul L Bollyky; Rebecca P Wu; Ben A Falk; James D Lord; S Alice Long; Anton Preisinger; Brandon Teng; Gregory E Holt; Nathan E Standifer; Kathleen R Braun; Cindy Fang Xie; Peter L Samuels; Robert B Vernon; John A Gebe; Thomas N Wight; Gerald T Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 3.  Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6.

Authors:  Svetlana Chapoval; Preeta Dasgupta; Nicolas J Dorsey; Achsah D Keegan
Journal:  J Leukoc Biol       Date:  2010-03-24       Impact factor: 4.962

4.  GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms.

Authors:  Palash Bhattacharya; Anupama Gopisetty; Balaji B Ganesh; Jian Rong Sheng; Bellur S Prabhakar
Journal:  J Leukoc Biol       Date:  2010-11-02       Impact factor: 4.962

Review 5.  Tolerizing allergic responses in the lung.

Authors:  C M Lloyd; J R Murdoch
Journal:  Mucosal Immunol       Date:  2010-05-26       Impact factor: 7.313

Review 6.  Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy.

Authors:  H W Chu; C M Lloyd; W Karmaus; P Maestrelli; P Mason; G Salcedo; J Thaikoottathil; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

7.  Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.

Authors:  John F Alcorn; Lisa M Rinaldi; Elizabeth F Jaffe; Mirjam van Loon; Jason H T Bates; Yvonne M W Janssen-Heininger; Charles G Irvin
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

8.  CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction.

Authors:  Giorgia Gri; Silvia Piconese; Barbara Frossi; Vanessa Manfroi; Sonia Merluzzi; Claudio Tripodo; Antonella Viola; Sandra Odom; Juan Rivera; Mario P Colombo; Carlo E Pucillo
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

9.  CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Erin E West; Matthew H Willett; Martin F Britos; Matthew R Pipeling; Roy G Brower; Rubin M Tuder; John F McDyer; Landon S King
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

Review 10.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.